Characteristic
|
Total [cases (%)]
|
---|
Age (months)
|
< 18
|
16 (15.8)
|
≥ 18
|
85 (84.2)
|
Sex
|
Male
|
57 (56.4)
|
Female
|
44 (43.6)
|
WBC (× 109/L)
|
> 10
|
17 (16.8)
|
4–10
|
60 (59.4)
|
< 4
|
24 (23.8)
|
Hemoglobin (g/L)
|
> 120
|
8 (7.9)
|
90–120
|
59 (58.4)
|
60–89
|
33 (32.7)
|
< 60
|
1 (1.0)
|
Platelet (× 109/L)
|
> 300
|
47 (46.5)
|
100–300
|
48 (47.5)
|
< 100
|
6 (6.0)
|
Risk stratification
|
Low-risk
|
1 (1.0)
|
Intermediate-risk
|
7 (6.9)
|
High-risk
|
93 (92.1)
|
Primary tumor site
|
Abdomen
|
88 (87.1)
|
Thorax
|
12 (11.9)
|
Neck
|
1 (1.0)
|
11q23 deletion
|
Yes
|
40 (39.6)
|
No
|
61 (60.4)
|
MYCN amplification
|
Yes
|
12 (11.9)
|
No
|
89 (88.1)
|
LDH (IU/L)
|
< 1500
|
79 (78.2)
|
≥ 1500
|
22 (21.8)
|
NSE (ng/mL)
|
< 370
|
60 (59.4)
|
≥ 370
|
41 (40.6)
|
Event
|
No event
|
49 (48.5)
|
Relapse/progression
|
13 (12.9)
|
Death
|
39 (38.6)
|
- WBC white blood cell, MYCN the v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog, LDH lactate dehydrogenase, NSE neuron-specific enolase